ATE219660T1 - Mittel zum einbringen polyanionischer materialien in zellen - Google Patents

Mittel zum einbringen polyanionischer materialien in zellen

Info

Publication number
ATE219660T1
ATE219660T1 AT95932591T AT95932591T ATE219660T1 AT E219660 T1 ATE219660 T1 AT E219660T1 AT 95932591 T AT95932591 T AT 95932591T AT 95932591 T AT95932591 T AT 95932591T AT E219660 T1 ATE219660 T1 AT E219660T1
Authority
AT
Austria
Prior art keywords
cells
polyanionic materials
polyanionic
introducing
agent
Prior art date
Application number
AT95932591T
Other languages
English (en)
Inventor
Steven Michial Ansell
Barbara Mui
Michael Hope
Original Assignee
Inex Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/442,267 external-priority patent/US5753613A/en
Application filed by Inex Pharmaceuticals Corp filed Critical Inex Pharmaceuticals Corp
Application granted granted Critical
Publication of ATE219660T1 publication Critical patent/ATE219660T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT95932591T 1994-09-30 1995-09-29 Mittel zum einbringen polyanionischer materialien in zellen ATE219660T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31639994A 1994-09-30 1994-09-30
US08/442,267 US5753613A (en) 1994-09-30 1995-05-16 Compositions for the introduction of polyanionic materials into cells
PCT/CA1995/000553 WO1996010390A1 (en) 1994-09-30 1995-09-29 Novel compositions for the introduction of polyanionic materials into cells

Publications (1)

Publication Number Publication Date
ATE219660T1 true ATE219660T1 (de) 2002-07-15

Family

ID=26980411

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95932591T ATE219660T1 (de) 1994-09-30 1995-09-29 Mittel zum einbringen polyanionischer materialien in zellen

Country Status (5)

Country Link
US (1) US5785992A (de)
EP (1) EP1179340A3 (de)
AT (1) ATE219660T1 (de)
CA (1) CA2200952C (de)
DE (1) DE69527206T2 (de)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674908A (en) * 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6989434B1 (en) 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7422902B1 (en) * 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) * 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
EP0855184A1 (de) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
US5965542A (en) * 1997-03-18 1999-10-12 Inex Pharmaceuticals Corp. Use of temperature to control the size of cationic liposome/plasmid DNA complexes
CA2289702C (en) 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6268534B1 (en) * 1998-02-23 2001-07-31 Ribozyme Pharmaceuticals, Inc. Process for the synthesis of N,N-Dioleyl-N,N-Dimethylammonium Chloride
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
CA2350882C (en) 1998-11-12 2011-02-22 Life Technologies Corporation Transfection reagents
DE19909115A1 (de) * 1999-03-03 2000-09-07 Florian Lang Verwendung von Ceramiden zur Behandlung cystischer Fibrose
WO2001005373A1 (en) * 1999-07-15 2001-01-25 Inex Pharmaceuticals Corp. Methods and apparatus for preparation of lipid vesicles
US7094423B1 (en) 1999-07-15 2006-08-22 Inex Pharmaceuticals Corp. Methods for preparation of lipid-encapsulated therapeutic agents
US20050249794A1 (en) * 1999-08-27 2005-11-10 Semple Sean C Compositions for stimulating cytokine secretion and inducing an immune response
AU7725500A (en) * 1999-09-30 2001-04-30 National Jewish Medical And Research Center Method for inhibition of pathogenic microorganisms
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
US20030096414A1 (en) * 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
WO2003039595A2 (en) * 2001-11-07 2003-05-15 Inex Pharmaceuticals Corporation Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
US7223887B2 (en) * 2001-12-18 2007-05-29 The University Of British Columbia Multivalent cationic lipids and methods of using same in the production of lipid particles
AU2003211103A1 (en) * 2002-02-13 2003-09-04 Northeastern University Intracellular delivery of therapeutic agents
US20040013649A1 (en) * 2002-05-10 2004-01-22 Inex Pharmaceuticals Corporation Cancer vaccines and methods of using the same
US20040009944A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
CA2513072A1 (en) * 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
AU2004257373B2 (en) 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
EP1660671A4 (de) * 2003-08-04 2007-09-12 Bayer Pharmaceuticals Corp Verfahren zum screening und zur identifizierung von verbindungen
CA2542099A1 (en) * 2003-10-11 2005-04-21 Inex Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
US20090209621A1 (en) 2005-06-03 2009-08-20 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
EP1948674A4 (de) 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc Modifizierte sirna-moleküle und anwendungen davon
JP2010513354A (ja) * 2006-12-19 2010-04-30 ノヴォソム アクチェンゲゼルシャフト トランスフェクションエンハンサー要素を含む脂質および脂質集合体
EP3434259A1 (de) 2007-05-04 2019-01-30 Marina Biotech, Inc. Aminosäurelipide und verwendungen davon
US20110091377A1 (en) 2007-05-11 2011-04-21 The Johns Hopkins University Biomarkers for melanoma
US9006191B2 (en) 2007-12-27 2015-04-14 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering RNA
WO2009129319A2 (en) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Silencing of csn5 gene expression using interfering rna
EP2279254B1 (de) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Neue lipidformulierungen zur nukleinsäurezuführung
US20110229498A1 (en) 2008-05-08 2011-09-22 The Johns Hopkins University Compositions and methods for modulating an immune response
US20110212021A1 (en) 2008-05-30 2011-09-01 Slack Frank J Targeted oligonucleotide compositions for modifying gene expression
AU2009303345B2 (en) 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
CN104382853A (zh) 2008-10-16 2015-03-04 玛瑞纳生物技术有限公司 基因沉默治疗剂的脂质体有效递送方法和组合物
CA2762095A1 (en) 2009-05-16 2010-11-25 Kunyuan Cui Compositions comprising cationic amphiphiles and colipids for delivering therapeutic molecules
ES2613498T3 (es) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
WO2011011447A1 (en) 2009-07-20 2011-01-27 Protiva Biotherapeutics, Inc. Compositions and methods for silencing ebola virus gene expression
WO2011038160A2 (en) 2009-09-23 2011-03-31 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes expressed in cancer
WO2011056682A1 (en) 2009-10-27 2011-05-12 The University Of British Columbia Reverse head group lipids, lipid particle compositions comprising reverse headgroup lipids, and methods for the delivery of nucleic acids
WO2011120023A1 (en) 2010-03-26 2011-09-29 Marina Biotech, Inc. Nucleic acid compounds for inhibiting survivin gene expression uses thereof
WO2011133584A2 (en) 2010-04-19 2011-10-27 Marina Biotech, Inc. Nucleic acid compounds for inhibiting hras gene expression and uses thereof
WO2011139842A2 (en) 2010-04-28 2011-11-10 Marina Biotech, Inc. Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
US20130123338A1 (en) 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
US10077232B2 (en) 2010-05-12 2018-09-18 Arbutus Biopharma Corporation Cyclic cationic lipids and methods of use
CN103154246B (zh) 2010-05-14 2015-11-25 达那-法伯癌症研究所 用于治疗白血病的组合物和方法
WO2011143651A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
JP2013530187A (ja) 2010-06-17 2013-07-25 ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 炎症性疾患を治療するための組成物及び方法。
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
EP2648706A4 (de) 2010-12-06 2014-07-23 Penn State Res Found Zusammensetzungen und verfahren im zusammenhang mit proliferativen erkrankungen
WO2012106490A1 (en) 2011-02-03 2012-08-09 The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Multivalent vaccines for rabies virus and filoviruses
EP2780455B1 (de) 2011-11-17 2017-07-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Therapeutische chimäre rna/dna-nanopartikel (np) mit automatischer erkennung
EP2780456A1 (de) 2011-11-17 2014-09-24 The U.S.A. as represented by the Secretary, Department of Health and Human Services Therapeutische rna schalter-zusammensetzungen und anwendungsverfahren dafür
CN104159615B (zh) * 2011-12-12 2017-08-18 协和发酵麒麟株式会社 含有阳离子性脂质的组合的脂质纳米粒子
JP6182457B2 (ja) 2011-12-12 2017-08-16 協和発酵キリン株式会社 カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
WO2013106358A1 (en) 2012-01-10 2013-07-18 Hussain M Mahmood Method of treating hyperlipidemia and atherosclerosis with mir-30c
US9352042B2 (en) 2012-02-24 2016-05-31 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
US10502737B2 (en) 2012-05-25 2019-12-10 The University Of Vermont And State Agriculture College Anti-thrombotic compositions and methods for assaying platelet reactivity and treatment selection
EP2968216A1 (de) 2013-03-15 2016-01-20 The Penn State Research Foundation Zusammensetzungen und verfahren mit leelamin und arachidonyltrifluormetylketon zur behandlung von krebs
CA2905649A1 (en) 2013-03-15 2014-09-18 The Penn State Research Foundation Compositions and methods including celecoxib and plumbagin relating to treatment of cancer
TW201534578A (zh) 2013-07-08 2015-09-16 Daiichi Sankyo Co Ltd 新穎脂質
WO2015011633A1 (en) 2013-07-23 2015-01-29 Protiva Biotherapeutics, Inc. Compositions and methods for delivering messenger rna
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
US10415037B2 (en) 2014-10-02 2019-09-17 Arbutus Biopharma Corporation Compositions and methods for silencing hepatitis B virus gene expression
WO2016197132A1 (en) 2015-06-04 2016-12-08 Protiva Biotherapeutics Inc. Treating hepatitis b virus infection using crispr
CN108350455A (zh) 2015-07-29 2018-07-31 阿布特斯生物制药公司 用于使b型肝炎病毒基因表达沉默的组合物和方法
MX2018002090A (es) 2015-08-24 2018-09-12 Halo Bio Rnai Therapeutics Inc Nanoparticulas de polinucleótido para modulación de expresión génica y sus usos.
WO2017081686A1 (en) 2015-11-10 2017-05-18 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Means and methods for reducing tumorigenicity of cancer stem cells
EP3386594B1 (de) 2015-12-11 2023-05-03 The General Hospital Corporation Kombination eines hemmer des pdgf-a rezeptors hemmers und eines hemmer der histon-lysin-demethylase zur behandlung arzneimitteltoleranter glioblastom
EP3439695B1 (de) 2016-04-04 2022-05-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Multivalente impfstoffe gegen tollwut- und coronaviren
US11191849B2 (en) 2016-06-30 2021-12-07 Arbutus Biopharma Corporation Compositions and methods for delivering messenger RNA
WO2018039131A1 (en) 2016-08-22 2018-03-01 Protiva Biotherapeutics, Inc. Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b
AU2017379901B2 (en) 2016-12-21 2024-02-15 Arbutus Biopharma Corporation Methods for ameliorating infusion reactions
EP3772928B1 (de) 2018-04-06 2025-02-26 Children's Medical Center Corporation Zusammensetzungen und verfahren zur prägung der umprogrammierung und modulation von somatischen zellen
WO2020033791A1 (en) 2018-08-09 2020-02-13 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
US20220175723A1 (en) 2019-04-22 2022-06-09 The Penn State Research Foundation Methods and compositions relating to inhibition of aldehyde dehydrogenases for treatment of cancer
SG11202113253SA (en) 2019-06-07 2021-12-30 Scribe Therapeutics Inc Engineered casx systems
WO2021145821A1 (en) * 2020-01-13 2021-07-22 Carmine Therapeutics Pte. Ltd. Nucleic acid loaded red blood cell extracellular vesicles
JP7709981B2 (ja) 2020-03-17 2025-07-17 ジェネヴァント サイエンシズ ゲーエムベーハー 肝星細胞への治療薬の脂質ナノ粒子送達のためのカチオン性脂質
JP2023530234A (ja) 2020-06-05 2023-07-14 ザ・ブロード・インスティテュート・インコーポレイテッド 新生物を治療するための組成物および方法
US12616678B2 (en) 2020-06-10 2026-05-05 The Penn State Research Foundation Methods to of aldehyde dehydrogenases for treatment of cancer
MX2023004299A (es) 2020-10-13 2023-07-07 Univ Pennsylvania Direccionamiento de células t cd4+ in vivo para terapeuticos de arnm.
AU2021392719B2 (en) 2020-12-03 2025-08-14 Scribe Therapeutics Inc. Engineered class 2 type v crispr systems
AU2021403156A1 (en) 2020-12-18 2023-07-13 Genevant Sciences Gmbh Peg lipids and lipid nanoparticles
AU2022290851A1 (en) 2021-06-08 2023-11-23 C4 Therapeutics, Inc. Therapeutics for the degradation of mutant braf
US20230046606A1 (en) 2021-07-15 2023-02-16 Turn Biotechnologies, Inc. Synthetic, persistent rna constructs with on/off mechanism for controlled expression and methods of use
US20230044997A1 (en) 2021-07-15 2023-02-09 Turn Biotechnologies, Inc. Synthetic, persistent rna constructs and methods of use for cell rejuvenation and for treatment
US20230042860A1 (en) 2021-07-15 2023-02-09 Turn Biotechnologies, Inc. Polycistronic expression vectors
IL311610A (en) 2021-09-21 2024-05-01 Scribe Therapeutics Inc Engineered CASX suppressor systems
KR20240090727A (ko) 2021-10-22 2024-06-21 세일 바이오메디슨스, 인크. Mrna 백신 조성물
US20250002941A1 (en) 2021-11-23 2025-01-02 Sail Biomedicines, Inc. A bacteria-derived lipid composition and use thereof
EP4452239A1 (de) 2021-12-20 2024-10-30 Sail Biomedicines, Inc. Zusammensetzungen mit mrna und lipidrekonstruierten pflanzenbotenstoffpackungen
KR20240146674A (ko) 2022-01-31 2024-10-08 제네반트 사이언시즈 게엠베하 지질 나노입자를 위한 이온화 가능한 양이온성 지질
AU2023269134A1 (en) 2022-05-09 2024-12-12 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
US20260191969A1 (en) 2022-05-30 2026-07-09 Kyushu University, National University Corporation Composition containing anionic long-chain lipid to be used for attenuating skin barrier function, and dispersion containing complex comprising cationic long-chain lipid, anionic long-chain lipid and drug dispersed therein
CA3257824A1 (en) 2022-06-02 2023-12-07 Scribe Therapeutics Inc. MODIFIED TYPE V, CLASS 2 CRISPR SYSTEMS
CN119301272A (zh) 2022-06-02 2025-01-10 瑞孚迪健康科学公司 腺相关病毒衣壳的dna含量的电泳介导的表征
CN119998446A (zh) 2022-06-07 2025-05-13 斯克里贝治疗公司 用于靶向pcsk9的组合物和方法
EP4536819A1 (de) 2022-06-07 2025-04-16 Scribe Therapeutics Inc. Zusammensetzungen und verfahren zum targeting von pcsk9
CN120659627A (zh) 2022-07-29 2025-09-16 瑞泽恩制药公司 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法
AU2023371614A1 (en) 2022-11-04 2025-05-15 Regeneron Pharmaceuticals, Inc. Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
EP4615424A1 (de) 2022-11-10 2025-09-17 Sail Biomedicines, Inc. Rna-zusammensetzungen mit lipidnanopartikeln oder lipidrekonstruierten natürlichen messenger-packs
AU2023379457A1 (en) 2022-11-14 2025-05-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
JP2026503676A (ja) 2023-01-27 2026-01-29 セイル バイオメディシンズ インコーポレイテッド 修飾脂質組成物およびその使用
WO2024206555A1 (en) 2023-03-29 2024-10-03 Scribe Therapeutics Inc. Compositions and methods for the targeting of pcsk9
TW202444914A (zh) 2023-03-29 2024-11-16 美商斯奎柏治療公司 抑制子融合蛋白系統
WO2024206676A1 (en) 2023-03-29 2024-10-03 Scribe Therapeutics Inc. Compositions and methods for the targeting of lpa
WO2024220712A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Vaccine compositions
WO2024220752A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Rna therapeutic compositions
EP4698150A1 (de) 2023-04-19 2026-02-25 Sail Biomedicines, Inc. Verabreichung von polynukleotiden aus lipidnanopartikeln mit rna und ionisierbaren lipiden
WO2024226499A1 (en) 2023-04-24 2024-10-31 The Broad Institute, Inc. Compositions and methods for modifying fertility
JP7544425B1 (ja) 2023-08-01 2024-09-03 ＮＯＶＩＧＯ Ｐｈａｒｍａ株式会社 固体粒子分散製剤
WO2025052278A1 (en) 2023-09-05 2025-03-13 Genevant Sciences Gmbh Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
WO2025075115A1 (ja) 2023-10-06 2025-04-10 ＮＯＶＩＧＯ Ｐｈａｒｍａ株式会社 脂質小胞および細胞への目的分子の導入方法、並びに抗体の分散製剤
WO2025096975A1 (en) 2023-11-02 2025-05-08 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of enhancing immune cell therapies by runx2 modulation
WO2025240940A1 (en) 2024-05-17 2025-11-20 Scribe Therapeutics Inc. Compositions and methods for the targeting of apolipoprotein c3
WO2026050217A2 (en) 2024-08-27 2026-03-05 Iovance Biotherapeutics, Inc. Engineered artificial antigen presenting cells and lipid nanoparticles for tumor infiltrating lymphocyte expansion
WO2026152023A1 (en) 2025-01-10 2026-07-16 Sail Biomedicines, Inc. Lipid compounds, lipid nanoparticle compositions and use thereof with polyribonucleotides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394372A (en) * 1980-12-22 1983-07-19 The Procter & Gamble Company Process for making lipid membrane structures
JPS6072831A (ja) * 1983-09-29 1985-04-24 Kao Corp ベシクル用組成物
GB2147243B (en) * 1983-10-01 1986-10-15 Standard Telephones Cables Ltd Applying thermoplastics sleeve to crush resistant tubing
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) * 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5234767A (en) * 1987-03-13 1993-08-10 Micro-Pak, Inc. Hybrid paucilamellar lipid vesicles
FR2645866B1 (fr) * 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5286634A (en) * 1989-09-28 1994-02-15 Stadler Joan K Synergistic method for host cell transformation
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes

Also Published As

Publication number Publication date
CA2200952C (en) 2006-04-11
DE69527206D1 (de) 2002-08-01
CA2200952A1 (en) 1996-04-11
EP1179340A3 (de) 2003-05-07
US5785992A (en) 1998-07-28
DE69527206T2 (de) 2003-02-27
EP1179340A2 (de) 2002-02-13

Similar Documents

Publication Publication Date Title
DE69527206D1 (de) Mittel zum einbringen polyanionischer materialien in zellen
BR8101853A (pt) Composicao alvejante liquida,processo para a preparacao de uma composicao alvejante liquida e processo para alvejamento
IE801820L (en) Antipode.
TW332782B (en) The filtering-material and method for de-bacteria
PT82127B (pt) Processo para a preparacao de carbamatos de fenilo
BR9505773A (pt) Compostos diquaternários úteis como ativadores de alvejamento e composiçoes contendo os mesmos
BR9306242A (pt) Processo para preparaçao de composiçoes detergentes líquidas tixotrópicas
BR9002720A (pt) Processo para produzir particulas detergentes altamente attivas,particulas assim obtidas e composicao compreendendo as mesmas
PT90535A (pt) Processo para a preparacao de composicoes detergentes liquidas fortes para a lavandaria contendo agentes tensio-activos anionicos e nao-ionicos, agentes formadores de detergencia e enzima proteolitico
BR8705812A (pt) Po detergente,processo para a preparacao de um po detergente e composicao detergente granular
IT8419646A0 (it) Processo per il bloccaggio dicomposti dello zolfo, che risultino come prodotti di reazione nella combustione di sostanze combustibili contenenti zolfo, in un impianto di combustione, mediante l'aggiunta di additivi.
IT1130452B (it) Composizioni ammorbidenti liquide per tessuti e procedimento per la loro preparazione
IT8048663A0 (it) Composizioni chimiche utili come agenti di collaggio per la carta eprocedimento di produzione
NO941104D0 (no) Asfaltblandinger, samt fremgangsmåte ved fremstilling derav
IT8449157A0 (it) Composti bisazoici contenenti gruppi solfo,loro preparazione e loro impiego come coloranti
GB2059619B (en) Contrast colourant for photopolymerizable compositions
ZA805517B (en) Sulphur concrete compositions, methods of forming articles therefrom and the articles as formed
ATE6778T1 (de) Chinazolinderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
BR8404190A (pt) Polimero adequado para uso como mascara de soldagem;composicao liquida;composicao fotopolimerizavel;composicao liquida fotopolimerizavel;processo para preparar polimero:processo para produzir mascara de soldagem no"hot melt"
ATE46518T1 (de) Sialosylcerebroside und verfahren zu ihrer herstellung.
AU2735199A (en) Novel cationic compounds, their use as coupling agents for oxidation dyeing of keratinous fibres, dyeing compositions and dyeing methods
BR8803768A (pt) Composicao odorante,processo para producao de compostos e uso dos ditos compostos
IE781659L (en) Pseudotrisaccharides
FI911023A7 (fi) Menetelmä alkyylitetrahydroantrahydrokinonien valmistamiseksi ja näitä sisältävät työliuokset antrakinonimenetelmällä suoritettavaa vetyperoksidivalmistusta varten
MY104777A (en) Benzoxazine dyes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties